Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145078 · ClinicalTrials.gov registry record · NA
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02145078: Clinical Trial NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT02145078 is a NA study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02145078, a NA study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This pilot clinical trial studies whether the levels of certain genes in the tissue and blood are related to how well patients with stage IV non-small cell lung cancer respond to chemotherapy. Genes may affect how sensitive or resistant tumors are to chemotherapy. Studying the levels of genes related to tumor response before and after chemotherapy may help doctors learn whether they can predict how well patients will respond to treatment.
Primary Outcome
A univariable regression of continuous disease response on baseline marker value will be performed. A multivariable regression model adjusted for clinical covariates will be evaluated as well. Expression levels of RRM1, TS, BRCA1, and other molecules and disease response after course 2 will be log-transformed.
Interventions
- OTHER laboratory biomarker analysis
- DRUG docetaxel
- DRUG gemcitabine hydrochloride
- DRUG pemetrexed disodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-03-07 |
| Phase | NA |
Why NCT02145078 stopped before completion
NCT02145078 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02145078 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02145078 about?
NCT02145078 is a clinical study titled "Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer". This pilot clinical trial studies whether the levels of certain genes in the tissue and blood are related to how well patients with stage IV non-small cell lung cancer respond to chemotherapy. Genes may affect how sensitive or resistant tumors are to chemotherapy. Studying the levels of genes relate...
What is the current status of trial NCT02145078?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2014-06. Estimated completion is 2017-03-07.
What interventions are being tested in trial NCT02145078?
The interventions under investigation include: laboratory biomarker analysis (OTHER), docetaxel (DRUG), gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT02145078?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02145078's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia